{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:27:34Z","timestamp":1785814054567,"version":"3.56.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Antibody-drug conjugates (ADCs) have emerged as promising targeted therapies for acute myeloid leukemia (AML). However, most ADCs exhibit off-target binding to normal hematopoietic stem and myeloid progenitor cells, resulting in adverse hematotoxicity and narrow therapeutic windows, thereby limiting their clinical application to young and fit patients with AML who are eligible for intensive curative therapies. Proteoglycans with high levels of the glycosaminoglycan oncofetal chondroitin sulfate (ofCS) are abundantly expressed in solid cancers but are absent or expressed at low levels in normal adult tissues. Here, we report high ofCS levels on bone marrow (BM) cells from patients with AML and patient-derived xenografts (PDXs) from these patients, whereas BM cells from healthy individuals showed low or undetectable ofCS levels. Consistently, an anti-ofCS antibody demonstrated binding to and internalization into AML cells, and anti-ofCS ADCs effectively killed AML cells in vitro. Moreover, anti-ofCS ADC treatment significantly prolonged survival of AML PDXs compared with controls and was associated with low toxicity. Thus, anti-ofCS ADCs could represent an effective therapy with acceptable toxicity for patients with AML, including those who are ineligible for or unresponsive to current intensive curative therapies. In conclusion, this study demonstrates, to our knowledge for the first time, that a glycosaminoglycan-like ofCS is a druggable target for the development of effective antibody-based AML therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024028147","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:17:02Z","timestamp":1765984622000},"page":"1229-1236","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1809-0929","authenticated-orcid":false,"given":"Joana","family":"Mujollari","sequence":"first","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"2VAR2 Pharmaceuticals ApS, Frederiksberg, Denmark"},{"name":"3VarCT Diagnostics, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7162-4158","authenticated-orcid":false,"given":"Montserrat","family":"Estruch","sequence":"additional","affiliation":[{"name":"4Biotech Research and Innovation Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"5Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6433-9748","authenticated-orcid":false,"given":"Priya","family":"Khadgawat","sequence":"additional","affiliation":[{"name":"4Biotech Research and Innovation Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"5Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Choudhary","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"2VAR2 Pharmaceuticals ApS, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0243-2248","authenticated-orcid":false,"given":"Tobias","family":"Gustavsson","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"2VAR2 Pharmaceuticals ApS, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-0716","authenticated-orcid":false,"given":"Robert","family":"Dagil","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"2VAR2 Pharmaceuticals ApS, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Redlinger","sequence":"additional","affiliation":[{"name":"6Institute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria"},{"name":"7Department of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-5118","authenticated-orcid":false,"given":"Caroline","family":"L\u00f8ppke","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"3VarCT Diagnostics, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9655-2106","authenticated-orcid":false,"given":"Elena Ethel","family":"Vidal-Calvo","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Anemone","family":"Nordmaj","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"2VAR2 Pharmaceuticals ApS, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-7514","authenticated-orcid":false,"given":"Thor Grundtvig","family":"Theander","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"2VAR2 Pharmaceuticals ApS, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5404-6483","authenticated-orcid":false,"given":"Olaf","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"8Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands"},{"name":"9Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7111-031X","authenticated-orcid":false,"given":"Yen","family":"Nguyen","sequence":"additional","affiliation":[{"name":"4Biotech Research and Innovation Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"5Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1944-0062","authenticated-orcid":false,"given":"Shuyu","family":"Qin","sequence":"additional","affiliation":[{"name":"4Biotech Research and Innovation Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"5Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4537-2505","authenticated-orcid":false,"given":"Anne Louise","family":"T\u00f8lb\u00f8ll S\u00f8rensen","sequence":"additional","affiliation":[{"name":"10Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"11Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-9601","authenticated-orcid":false,"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[{"name":"4Biotech Research and Innovation Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"10Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"11Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-0844","authenticated-orcid":false,"given":"Bo Torben","family":"Porse","sequence":"additional","affiliation":[{"name":"4Biotech Research and Innovation Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"5Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"11Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-2664","authenticated-orcid":false,"given":"Brigitte","family":"Kircher","sequence":"additional","affiliation":[{"name":"7Department of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5626-8271","authenticated-orcid":false,"given":"Jan","family":"Mueller","sequence":"additional","affiliation":[{"name":"6Institute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria"},{"name":"7Department of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5865-2034","authenticated-orcid":false,"given":"Mette \u00d8rskov","family":"Agerb\u00e6k","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"3VarCT Diagnostics, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salanti","sequence":"additional","affiliation":[{"name":"1Centre for translational Medicine and Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"2VAR2 Pharmaceuticals ApS, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4239-4939","authenticated-orcid":false,"given":"Kim","family":"Theilgaard-M\u00f6nch","sequence":"additional","affiliation":[{"name":"4Biotech Research and Innovation Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"},{"name":"5Finsen Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"10Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"},{"name":"11Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"},{"name":"12Department of Hematology, University Hospital of Odense, Odense, Denmark"},{"name":"13Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026031211215956800_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026031211215956800_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2026031211215956800_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"2026031211215956800_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2026031211215956800_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2026031211215956800_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody\u2013drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2026031211215956800_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/2643-3230.BCD-23-0202","article-title":"Recent advances in immune-based therapies for acute myeloid leukemia","volume":"5","author":"Restelli","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"8014","key":"2026031211215956800_bib8","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/d41586-024-01426-5","article-title":"How antibody\u2013drug conjugates aim to take down cancer","volume":"629","author":"Plackett","year":"2024","journal-title":"Nature"},{"issue":"9825","key":"2026031211215956800_bib9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"2026031211215956800_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/13543784.2018.1452911","article-title":"Investigational CD33-targeted therapeutics for acute myeloid leukemia","volume":"27","author":"Walter","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"2026031211215956800_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fonc.2020.00127","article-title":"DNA-PK inhibitor, M3814, as a new combination partner of Mylotarg in the treatment of acute myeloid leukemia","volume":"10","author":"Carr","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"2026031211215956800_bib12","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"2026031211215956800_bib13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","article-title":"An anti-CLL-1 antibody-drug conjugate for the treatment of acute myeloid leukemia","volume":"25","author":"Zheng","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2026031211215956800_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2021015246","article-title":"Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML","volume":"141","author":"Roas","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026031211215956800_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026031211215956800_bib16","doi-asserted-by":"crossref","first-page":"656218","DOI":"10.3389\/fonc.2021.656218","article-title":"Immunotherapy in acute myeloid leukemia: where we stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"2026031211215956800_bib17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2015.09.003","article-title":"Targeting human cancer by a glycosaminoglycan binding malaria protein","volume":"28","author":"Salanti","year":"2015","journal-title":"Cancer Cell"},{"issue":"6","key":"2026031211215956800_bib18","doi-asserted-by":"crossref","first-page":"101391","DOI":"10.1016\/j.jbc.2021.101391","article-title":"The specificity of the malarial VAR2CSA protein for chondroitin sulfate depends on 4-O-sulfation and ligand accessibility","volume":"297","author":"Spliid","year":"2021","journal-title":"J Biol Chem"},{"issue":"1","key":"2026031211215956800_bib19","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.1038\/s41467-024-51781-0","article-title":"Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate","volume":"15","author":"Vidal-Calvo","year":"2024","journal-title":"Nat Commun"},{"issue":"12","key":"2026031211215956800_bib20","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1541-7786.MCR-16-0103","article-title":"Oncofetal chondroitin sulfate glycosaminoglycans are key players in integrin signaling and tumor cell motility","volume":"14","author":"Clausen","year":"2016","journal-title":"Mol Cancer Res"},{"issue":"7","key":"2026031211215956800_bib21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1742-4658.2012.08529.x","article-title":"Glycosaminoglycans: key players in cancer cell biology and treatment","volume":"279","author":"Afratis","year":"2012","journal-title":"FEBS J"},{"issue":"8","key":"2026031211215956800_bib22","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/leu.2015.30","article-title":"Cellular origin of prognostic chromosomal aberrations in AML patients","volume":"29","author":"Mora-Jensen","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2026031211215956800_bib23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood-2013-02-485771","article-title":"Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients","volume":"123","author":"Rapin","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2026031211215956800_bib24","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","article-title":"NOD\/SCID\/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells","volume":"100","author":"Ito","year":"2002","journal-title":"Blood"},{"issue":"13","key":"2026031211215956800_bib25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/bloodadvances.2018015743","article-title":"Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin","volume":"2","author":"Reckzeh","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2026031211215956800_bib26","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/s41467-018-05793-2","article-title":"The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAM-independent manner","volume":"9","author":"Agerb\u00e6k","year":"2018","journal-title":"Nat Commun"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/11\/1229\/2508923\/blood_bld-2024-028147-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/11\/1229\/2508923\/blood_bld-2024-028147-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:22:08Z","timestamp":1773328928000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/11\/1229\/557372\/The-glycosaminoglycan-oncofetal-chondroitin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024028147","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,12]]},"published":{"date-parts":[[2026,3,12]]}}}